5-Fluorouracil: mechanisms of action and clinical strategies
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“5-FU exerts its anti-cancer effects by inhibiting thymidylate synthase (TS) and incorporating its metabolites into RNA and DNA [4].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“5-FU mainly destroys the deoxynucleotide pool required for DNA replication by inhibiting thymidylate synthase (TS), and mixes its metabolites into RNA and DNA to exert anti-tumor effects [4,127].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“Several studies have shown that the high expression of TS is a crucial determinant of CRC resistance to 5-FU”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“and 5-FU intervention can also increase the expression of TS [4,9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“MutSα recognizes and associates with FdU:G mismatch pairs in an in vitro binding experiment”
From Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress (2014) · cites this paper as [210]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259 · cited 1×
“Irinotecan is a topoisomerase I inhibitor and is active in the first- and second-line treatment of advanced colorectal cancer, in which it has shown improved survival and quality of life when compared with best supportive care in patients who have failed 5-FU/L”
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Research works printed but not linked: 2
- Rutman, R. J., Cantarow, A. & Paschkis, K. E. Studies on 2-acetylaminofluorene carcinogenesis: III. The utilization of uracil-2-C14 by pre–neoplastic rat liver. Cancer Res. 14, 119 (1954).
- Jackson, R. C. & Grindley, G. B. The Biochemical Basis for Methotrexate Cytotoxicity (eds Sirotnak, F. M., Burchall, J. J., Ensminger, W. D. & Montgomery, J. A.) 289–315 (Academic, New York, 1984).
Cited by
Items 301–400 of 1,028
Offer, S. M., Wegner, N. J., Fossum, C. C., Wang, K., & Diasio, R. B. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3858 · Cited by 121
Base excision repair and its implications to cancer therapy
Grundy, G. J., & Parsons, J. L. (2020) · Essays in Biochemistry · doi:10.1042/ebc20200013 · Cited by 137
Mitani, Y., Oue, N., Matsumura, S., Yoshida, K., Noguchi, T., Ito, M., Tanaka, S., Kuniyasu, H., Kamata, N., & Yasui, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210215 · Cited by 122
“Several molecules associated with resistance to 5-FU have been identified (reviewed by Longley et al., 2003).”
BackgroundRegulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications
Kohnken, R., Kodigepalli, K. M., & Wu, L. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0446-6 · Cited by 123
“Methotrexate and similar compounds that inhibit dihydrofolate reductase required for purine biosynthesis [34], are widely used in chemotherapy for solid and lymphocytic tumors.”
BackgroundDNA replication stress and cancer chemotherapy
Kitao, H., Iimori, M., Kataoka, Y., Wakasa, T., Tokunaga, E., Saeki, H., Oki, E., & Maehara, Y. (2017) · Cancer Science · doi:10.1111/cas.13455 · Cited by 146
“part, 5-FU is converted to fluorouridine phosphate and incorporated into RNA.(42) 5-FU is also converted to fluorodeoxyuridine phosphate and fluorodeoxyuridine monophosphate, which directly binds and strongly inhibits thymidylate synthase and suppresses de novo thymidylate and dTTP synthesis.”
BackgroundInfluentialApigenin: A natural bioactive flavone-type molecule with promising therapeutic function
Kashyap, D., Sharma, A., Tuli, H., Sak, K., Garg, V., Buttar, H., Setzer, W., & Sethi, G. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.07.037 · Cited by 99
Mechanistic and Predictive Profiling of 5-Fluorouracil Resistance in Human Cancer Cells
Wang, W., Cassidy, J., O’Brien, V., Ryan, K. M., & Collie-Duguid, E. S. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0970 · Cited by 120
“In cancer cells, 5-FU is converted to several active metabolites intracellularly (fluorodeoxyuridine monophosphate, fluorodeoxyuridine triphosphate, and fluorouridine triphosphate) that are cytotoxic (1).”
BackgroundInfluentialGonzález‐Sarrías, A., Tomé‐Carneiro, J., Bellesia, A., Tomás-Barberán, F. A., & Espín, J. C. (2015) · Food & Function · doi:10.1039/c5fo00120j · Cited by 129
Farès, M., Abou‐Seri, S. M., Abdel‐Aziz, H. A., Abbas, S. E.-S., Youssef, M., & Eladwy, R. A. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.06.027 · Cited by 119
The combination of curcumin and 5-fluorouracil in cancer therapy
Wei, Y., Yang, P., Cao, S., & Zhao, L. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0979-x · Cited by 128
“5-FU alone or in combination with other chemotherapeutic drugs has been widely used for the treatment of patients with breast cancer clinically (Longley et al. 2003; Takahashi et al. 2014; Wu et al. 2015).”
BackgroundPhotodynamic therapy for skin cancer: How to enhance drug penetration?
Champeau, M., Vignoud, S., Mortier, L., & Mordon, S. R. (2019) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2019.111544 · Cited by 124
“One metabolite is a thymidylate synthase inhibitor that interrupts the synthesis of pyrimidine thymidine, which is a nucleoside required for DNA replication [89].”
BackgroundYi, G. Y., Kim, M. J., Kim, H. I., Park, J., & Baek, S. H. (2022) · Antioxidants · doi:10.3390/antiox11040625 · Cited by 136
“In particular, it has a significant anti-cancer effect in colon cancer by inhibiting thymidylate synthase and dysfunction of its metabolites into RNA and DNA [55].”
BackgroundFan, C., Chen, J., Wang, Y., Wong, Y., Zhang, Y., Zheng, W., Cao, W., & Chen, T. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.07.002 · Cited by 118
Justino, P. F. C., Melo, L. F. M., Nogueira, A. F., Costa, J. V. G., Silva, L. M. N., Santos, C. M., Mendes, W. D. O., Costa, M. R., Franco, Á. X., Lima, A. Â. M., et al. (2014) · British Journal Of Nutrition · doi:10.1017/s0007114513004248 · Cited by 118
“The anti-metabolite agent 5-fluorouracil (5-FU) is used in the treatment of a range of cancers, including colorectal and breast cancers((9,10)), but it is known to induce intestinal damage, especially intestinal mucositis((11)), and intestinal stem cell apoptosis((12)).”
Li, B., Tang, J., Chen, W., Hao, G., Kurniawan, N. D., Gu, Z., & Xu, Z. P. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.055 · Cited by 118
Microneedles for gene and drug delivery in skin cancer therapy
Zhi, D., Yang, T., Zhang, T., Yang, M. J., Zhang, S., & Donnelly, R. F. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.009 · Cited by 124
McGuigan, C., Murziani, P. G. S., Ślusarczyk, M., Gönczy, B., Voorde, J. V., Liekens, S., & Balzarini, J. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200815w · Cited by 131
de la Cruz-Morcillo, M. A., Valero, M. L. L., Callejas-Valera, J. L., Arias-González, L., Melgar-Rojas, P., Galán-Moya, E. M., García-Gil, E., García-Cano, J., & Sánchez-Prieto, R. (2012) · Oncogene · doi:10.1038/onc.2011.321 · Cited by 117
“T The main target of 5-FU is the thymidylate synthase enzyme, which blocks the normal synthesis of DNA through inhibition of the synthesis of thymidine, but also interferes with RNA processing (for review, see Longley et al. , 2003).”
RetractedDUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer
Zhang, Q., Zhang, Z.-Y., Du, H., Li, S., Tu, R., Jia, Y., Zheng, Z., Song, X., Du, R., & Zhang, X. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0303-z · Cited by 119
Bruinsmann, F. A., Richter Vaz, G., de Cristo Soares Alves, A., Aguirre, T., Raffin Pohlmann, A., Stanisçuaski Guterres, S., & Sonvico, F. (2019) · Molecules · doi:10.3390/molecules24234312 · Cited by 118
Yue, X., Wen, S., Ding, L., Yan, M., Chang, S., Zhang, M., Shuang-yu, L., Qian, X., Ma, J., & Wu, L. (2022) · BMC Immunology · doi:10.1186/s12865-022-00495-3 · Cited by 117
“5-Fluorouracil (5-FU) is a commonly used tumor chemotherapy drug that inhibits tumor cell proliferation by interfering with tumor cell DNA synthesis and is widely used to treat various cancers [4, 5].”
BackgroundKim, H., Yoon, Y., Kim, J., Han, S., Hur, H.-S., Park, J., Lee, J. H., Oh, D., Im, S., Bang, Y., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005933 · Cited by 117
“Fluoropyrimidines such as 5-FU are extensively utilized in the treatment of colorectal, breast, and aerodigestive tract cancers, and are intracellularly converted to 5fluoro- deoxyuridine-monophosphate (FdUMP), thus forming a stable tertiary complex and inhibiting TS [12–14].”
Mellor, H. R., Ferguson, D. J. P., & Callaghan, R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602710 · Cited by 116
“The mechanism of action of the uracil analogue 5-FU is through incorporation of its metabolites into RNA and DNA and through thymidylate synthase inhibition (Longley et al, 2003), which is required for DNA replication and repair.”
BackgroundHigh-Frequency Mechanical Properties of Tumors Measured by Brillouin Light Scattering
Margueritat, J., Virgone‐Carlotta, A., Monnier, S., Delanoë‐Ayari, H., Mertani, H. C., Berthelot, A., Martinet, Q., Dagany, X., Rivière, C., Rieu, J.-P., et al. (2019) · Physical Review Letters · doi:10.1103/physrevlett.122.018101 · Cited by 127
Decellularized Extracellular Matrix for Cancer Research
Hoshiba, T. (2019) · Materials · doi:10.3390/ma12081311 · Cited by 116
Lin, X., Zhou, L., Liu, C., Zeng, F., Yuan, Y., Zhou, Q., Li, S., Wu, Y., Wang, J., Wu, D., et al. (2021) · EMBO Reports · doi:10.15252/embr.202052124 · Cited by 123
“Many studies have confirmed that the rapid development of CDDP resistance is one of the main contributors to GC treatment failure (Longley et al , 2003).”
Gmeiner, W. H., & Okechukwu, C. C. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.136 · Cited by 131
Capecitabine: an overview of the side effects and their management
Saif, M. W., Katirtzoglou, N. A., & Syrigos, K. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f945aa · Cited by 129
An Integrated In Vitro and In Vivo High-Throughput Screen Identifies Treatment Leads for Ependymoma
Atkinson, J. M., Shelat, A. A., Carcaboso, A. M., Kranenburg, T. A., Arnold, L. A., Boulos, N., Wright, K., Johnson, R. A., Poppleton, H., Mohankumar, K. M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.013 · Cited by 117
“The ependymoma-selective activity of 5-FU in our HTS and relatively low expression of TYMS (Figure 5C) —the principal cellular target of 5-FU—in mEP cells, suggest this drug as a rational treatment of cerebral ependymoma (Longley et al., 2003).”
Montrose, D. C., Saha, S., Foronda, M., McNally, E. M., Chen, J. B., Zhou, X. K., Ha, T., Krumsiek, J., Büyüközkan, M., Verma, A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1541 · Cited by 124
“The latter mechanism results in profound nucleotide imbalances and DNA damage, which can lead to cell death (36).”
BackgroundCurcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer
Farghadani, R., & Naidu, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042144 · Cited by 133
Lucena, F. R. S., de Araújo, L. C. C., Rodrigues, M. D. D., da Silva, T. G., Pereira, V. R. A., Militão, G. C. G., Fontes, D. A. F., Neto, P. J. R., da Silva, F. F., & do Nascimento, S. C. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.06.003 · Cited by 121
“Since 5-FU interferes with DNA synthesis, it principally acts as a thymidylate synthase inhibitor [6,7].”
BackgroundIntralesional agents in the management of cutaneous malignancy: A review
Good, L. M., Miller, M. D., & High, W. A. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.12.013 · Cited by 126
Lipid prodrug nanocarriers in cancer therapy
Mura, S., Bui, D. T., Couvreur, P., & Nicolas, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.021 · Cited by 122
“Although to a lesser extent, the prodrug approach has been applied to fluoropyrimidine 5fluorouracil (5-FU), a drug widely used in the treatment of advanced colorectal and breast cancers [30], and its analogue floxuridine (5-fluoro-2’-deoxyuridine, FUdR).”
BackgroundWu, J., Cui, Y., Sun, X., Cao, G., Li, B., Ikeda, D. M., Kurian, A. W., & Li, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2415 · Cited by 115
“The disturbance of pyrimidine metabolism is consistent with the fact that the antimetabolite drugs such as fluorouracil and capecitabine are often effective treatments for breast cancer (47).”
Sen, K., Banerjee, S., & Mandal, M. (2019) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2019.04.035 · Cited by 110
Translating DPYD Genotype into DPD Phenotype: Using the DPYD Gene Activity Score
Henricks, L. M., Lunenburg, C. A. T. C., Meulendijks, D., Gelderblom, H. A. J., Cats, A., Swen, J. J., Schellens, J. H. M., & Guchelaar, H. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.70 · Cited by 114
5-Fluorouracil Is Efficiently Removed From DNA by the Base Excision and Mismatch Repair Systems
Fischer, F., Baerenfaller, K., & Jiricny, J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.09.003 · Cited by 116
Significance of thymidylate synthase for resistance to pemetrexed in lung cancer
Ozasa, H., Oguri, T., Uemura, T., Miyazaki, M., Maeno, K., Sato, S., & Ueda, R. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01358.x · Cited by 114
MBD4 and TDG: Multifaceted DNA glycosylases with ever expanding biological roles
Sjolund, A. B., Senejani, A. G., & Sweasy, J. B. (2013) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2012.11.001 · Cited by 113
“This includes four mRNA variant submissions which are translated into two forms of full-length MBD4 proteins with sizes equaling 580 aa (Accession number AF072250, AF114784, NM_003925) or 574 aa (Accession number BC011752) long proteins (Figure 1).”
BackgroundInfluentialPolymeric nanoparticles for colon cancer therapy: overview and perspectives
You, X., Kang, Y., Hollett, G., Chen, X., Zhao, W., Gu, Z., & Wu, J. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb01925k · Cited by 113
Wang, R.-X., Ou, Y., Chen, Y., Ren, T.-B., Yuan, L., & Zhang, X.-B. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c13851 · Cited by 113
Bracht, K., Nicholls, A. M., Liu, Y., & Bodmer, W. F. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605780 · Cited by 110
“…that, after conversion into its main active metabolites (FdÌMP, FdUTP, and FUTP), induces, among other effects, RNA and DNA damage through incorporation of its metabolites into nucleic acids, and inhibition of thymidylate synthase (TS) and therefore DNA synthesis (Longley et al, 2003).”
BackgroundBase Excision by Thymine DNA Glycosylase Mediates DNA-Directed Cytotoxicity of 5-Fluorouracil
Kunz, C., Focke, F., Saito, Y., Schuermann, D., Lettieri, T., Selfridge, J., & Schär, P. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000091 · Cited by 117
“with futile cycles of base excision repair (BER) [2,10,11].”
BackgroundInfluentialThe mismatch repair-dependent DNA damage response: Mechanisms and implications
Gupta, D., & Heinen, C. D. (2019) · DNA Repair · doi:10.1016/j.dnarep.2019.03.009 · Cited by 112
Tsvetkova, D. D., & Ivanova, S. A. (2022) · Molecules · doi:10.3390/molecules27082466 · Cited by 121
DNA-Based Nanomedicine with Targeting and Enhancement of Therapeutic Efficacy of Breast Cancer Cells
Zhan, Y., Ma, W., Zhang, Y., Mao, C., Shao, X., Xie, X., Wang, F., Liu, X., Li, Q., & Lin, Y. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b03449 · Cited by 116
Andersen, S. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh347 · Cited by 111
Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies
Sztiller-Sikorska, M., & Czyż, M. (2020) · Pharmaceuticals · doi:10.3390/ph13080194 · Cited by 113
“Thus, 5-fluorouracil (5-FU) is an important element of chemotherapy in many types of cancer [131].”
BackgroundAptamers in biomedicine: Selection strategies and recent advances
Ștefan, G., Hosu, O., Wael, K. D., Lobo-Castañón, M. J., & Cristea, C. (2021) · Electrochimica Acta · doi:10.1016/j.electacta.2021.137994 · Cited by 120
5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING
Tian, J., Zhang, D., Kurbatov, V., Wang, Q., Wang, Y., Fang, D., Wu, L., Bosenberg, M., Muzumdar, M. D., Khan, S. A., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020106065 · Cited by 116
“…including but not limited to the overexpression of thymidylate synthase, increased catabolism of 5-FU into inactive forms, and the expression of multidrug resistance proteins (Copur et al, 1995; Danenberg et al, 1995; Takebe et al, 2001; Longley et al, 2003; Zhang et al, 2008; Kikuchi et al, 2015).”
Gold nanoparticles enhance 5-fluorouracil anticancer efficacy against colorectal cancer cells
Safwat, M. A., Soliman, G. M., Sayed, D., & Attia, M. A. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.09.076 · Cited by 109
Layered inorganic nanocomposites: A promising carrier for 5-fluorouracil (5-FU)
Kevadiya, B. D., Patel, T., Jhala, D., Thumbar, R. P., Brahmbhatt, H. R., Pandya, M. P., Rajkumar, S., Jena, P. K., Joshi, G. V., Gadhia, P. K., et al. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.01.004 · Cited by 113
“It is a pyrimidine analog that inhibits the biosynthesis of deoxyribonucleotides for DNA replication by inhibiting thymidylate synthase activity, leading to thymidine depletion, incorporation of deoxyuridine triphosphate into DNA and cell death [10,11].”
BackgroundAmasya, G., Aksu, B., Badıllı, U., Onay-Beşikçi, A., & Tarımcı, N. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.03.056 · Cited by 113
Mou, Q., Ma, Y., Ding, F., Gao, X., Yan, D., Zhu, X., & Zhang, C. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b13875 · Cited by 109
Antibody–drug conjugates in cancer therapy: current landscape, challenges, and future directions
Chen, B., Zheng, X., Wu, J., Chen, G., Yu, J. Q., Xu, Y. X., Wu, W. K. K., Tse, G. M.-K., To, K. F., & Kang, W. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02489-2 · Cited by 133
“However, their limited selectivity often results in substantial off-target toxicities, including myelosuppression, gastrointestinal damage, and organ injury, underscoring the urgent need for more precise treatment approaches [8–10].”
Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections
Soo, V. W. C., Kwan, B. W., Quezada, H., Castillo‐Juárez, I., Peréz-Eretza, B., García-Contreras, S. J., Martínez‐Vázquez, M., Wood, T. K., & García‐Contreras, R. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160930131737 · Cited by 116
The Network of Non-coding RNAs in Cancer Drug Resistance
Corrà, F., Agnoletto, C., Minotti, L., Baldassari, F., & Volinia, S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00327 · Cited by 111
“It interferes with DNA replication by interrupting the synthesis of pyrimidine thymidine and thereby leading to cell cycle arrest or cell death (368, 369).”
BackgroundPersonalized medicine in breast cancer: pharmacogenomics approaches
Jeibouei, S., Akbari, M. E., Kalbasi, A., Aref, A. R., Ajoudanian, M., Rezvani, A., & Zali, H. (2019) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s167886 · Cited by 124
Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response
Ariav, Y., Ch’ng, J., Christofk, H. R., Ron‐Harel, N., & Erez, A. (2021) · Science Advances · doi:10.1126/sciadv.abg6165 · Cited by 118
“Inhibitors of pyrimidine biosynthesis currently used for cancer treatment include 5-fluorouracil, a thymidylate synthase inhibitor, and methotrexate, which inhibits dihydrofolate reductase and causes a drop in cellular levels of thymidine (77, 78).”
Chen, F., Zhuang, M., Zhong, C., Peng, J., Wang, X., Li, J., Chen, Z., & Huang, Y. (2014) · Oncology Reports · doi:10.3892/or.2014.3550 · Cited by 116
Paschall, A. V., Yang, D., Lu, C., Choi, J.-H., Li, X., Liu, F., Figueroa, M., Oberlies, N. H., Pearce, C., Bollag, W. B., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402243 · Cited by 107
“of resistance to 5-FU is often inevitable in human CRC patients (24).”
BackgroundVenkataramanan, N. S., Suvitha, A., & Kawazoe, Y. (2017) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2017.09.022 · Cited by 108
Beyond the Warburg effect: How do cancer cells regulate one-carbon metabolism?
Rosenzweig, A., Blenis, J., & Gomes, A. P. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00090 · Cited by 107
“Another commonly used anti-cancer treatment, 5-fluorouracil (5-FU), is known to inhibit thymidylate synthase (TYMS), which catalyzes the transfer of a one-carbon unit from methylene-THF onto dUMP to make dTMP (Longley et al., 2003).”
BackgroundGonzález‐Vallinas, M., Molina, S., Vicente, G., de la Cueva, A., Vargas, T., Santoyo, S., García‐Risco, M. R., Fornari, T., Reglero, G., & de Molina, A. R. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.03.010 · Cited by 111
PSMA-Targeted Theranostic Nanoplex for Prostate Cancer Therapy
Chen, Z., Penet, M., Nimmagadda, S., Li, C., Banerjee, S. R., Winnard, P. T., Artemov, D., Glunde, K., Pomper, M. G., & Bhujwalla, Z. M. (2012) · ACS Nano · doi:10.1021/nn301725w · Cited by 107
“imidine dehydrogenase (DPD), which catabolizes 5-FU to dihydrofluorouracil (DHFU).(45) This may, however, be”
Kovács, R., Csenki, Z., Bakos, K., Urbányi, B., Horváth, Á., Garaj‐Vrhovac, V., Gajski, G., Gerić, M., Negreira, N., de Alda, M. L., et al. (2015) · Water Research · doi:10.1016/j.watres.2015.03.025 · Cited by 109
“85 The fluoropyrimidine 5-fluorouracil (5-FU) is an antimetabolite that exerts its 86 anticancer effects through inhibition of DNA synthesis and replication, by inhibition of 87 thymidylate synthase, and by incorporation of 5-FU metabolites into RNA and DNA 88 (Longley et al. 2003).”
BackgroundMethodZahed, F. M., Hatamluyi, B., Lorestani, F., & Es’haghi, Z. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.08.004 · Cited by 107
Redox Imbalance in the Development of Colorectal Cancer
Liu, H., Liu, X., Zhang, C., Zhu, H., Xu, Q., Bu, Y., & Lei, Y. (2017) · Journal of Cancer · doi:10.7150/jca.18735 · Cited by 114
“For example, in vitro study observed that 5-Fu treatment in CRC cells generated O2− that positively regulated p53 proteins and thereby induced cancer cell apoptosis [142, 143].”
BackgroundBalaji, A., Vellayappan, M. V., John, A., Subramanian, A. P., Jaganathan, S. K., Supriyanto, E., & Razak, S. I. A. (2015) · RSC Advances · doi:10.1039/c5ra07595e · Cited by 115
Núñez‐Sánchez, M. Á., González‐Sarrías, A., Romo‐Vaquero, M., García-Villalba, R., Selma, M. V., Tomás-Barberán, F. A., García‐Conesa, M., & Espín, J. C. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400866 · Cited by 116
“This knowledge has much improved the cost-effectiveness ratio of 5-FU [60].”
BackgroundPranzini, E., Pardella, E., Muccillo, L., Leo, A., Nesi, I., Santi, A., Parri, M., Zhang, T., Uribe, A. H., Lottini, T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111233 · Cited by 112
Caffeic Acid Phenethyl Ester Is a Potential Therapeutic Agent for Oral Cancer
Kuo, Y., Jim, W.-T., Su, L., Chung, C., Lin, C., Huo, C., Tseng, J., Huang, S., Lai, C., Chen, B., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160510748 · Cited by 110
“and DNA as well as by inhibiting the nucleotide synthetic enzyme thymidylate synthase [93].”
BackgroundAntimetabolite Radiosensitizers
Shewach, D. S., & Lawrence, T. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5287 · Cited by 116
Common gene polymorphisms, cancer progression and prognosis
Loktionov, A. S. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.02.009 · Cited by 115
Zhang, Y., Talmon, G., & Wang, J. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.200 · Cited by 104
“pyrimidine thymidine, a nucleoside required for DNA replication, by blocking the activity of thymidylate synthase.(2)”
MethodRobinson, A. D., Eich, M., & Varambally, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.11.013 · Cited by 110
Jubeen, F., Liaqat, A., Amjad, F., Sultan, M., Iqbal, S. Z., Sajid, I., Niazi, M. B. K., & Sher, F. (2020) · Crystal Growth & Design · doi:10.1021/acs.cgd.9b01570 · Cited by 105
Advances in LDH coatings on Mg alloys for biomedical applications: A corrosion perspective
Tan, J. K. E., Balan, P., & Birbilis, N. (2020) · Applied Clay Science · doi:10.1016/j.clay.2020.105948 · Cited by 104
Mhaidat, N. M., Bouklihacene, M., & Thorne, R. F. (2014) · Oncology Letters · doi:10.3892/ol.2014.2211 · Cited by 106
“The chemotherapeutic agent, 5‑fluorouracil (5‑FU), induces cytotoxic effects via targeting the metabolism of RNA bases (3).”
RetractedSalem, D. S., Sliem, M. A., Elsesy, M. E., Shouman, S. A., & Badr, Y. A. (2018) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2018.03.024 · Cited by 108
Expanding the applications of microneedles in dermatology
Sabri, A. H. B., Ogilvie, J., Hamid, K. A., Shpadaruk, V., McKenna, J., Segal, J. I., Scurr, D. J., & Marlow, M. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.05.001 · Cited by 104
DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage
Reuvers, T. G. A., Kanaar, R., & Nonnekens, J. (2020) · Cancers · doi:10.3390/cancers12082098 · Cited by 116
“Well-known examples are nucleoside analogs such as 5-fluorouacil (5-FU), which can both inhibit the synthesis of the nucleoside thymidine and, after metabolism of the drug into a nucleotide analog, can be incorporated in the DNA [82].”
BackgroundRamesh, D., Vijayakumar, B. G., & Kannan, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112801 · Cited by 106
Shang, J., Yang, F., Wang, Y., Wang, Y., Xue, G., Mei, Q., Wang, F., & Sun, S. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24721 · Cited by 103
“It exerts its anticancer effects through the inhibition of thymidylate synthase and the incorporation of its active metabolites into RNA and DNA, so as to influence the uracil metabolism, which is reported as a potential target for antimetabolite chemotherapy [Longley et al., 2003; Karasawa et al., 2009].”
BackgroundFoloppe, J., Kintz, J., Futin, N., Findeli, A., Cordier, P., Schlesinger, Y., Hoffmann, C., Tosch, C., Balloul, J.-M., & Erbs, P. (2008) · Gene Therapy · doi:10.1038/gt.2008.82 · Cited by 119
Thymidine Phosphorylase in Cancer; Enemy or Friend?
Elamin, Y. Y., Rafee, S., Osman, N., O'Byrne, K. J., & Gately, K. A. (2015) · Cancer Microenvironment · doi:10.1007/s12307-015-0173-y · Cited by 108
“The mean TP mRNA level in the nonresponding tumours was 2.6-fold higher than that of the responding patients .”
InfluentialMeulendijks, D., Cats, A., Beijnen, J. H., & Schellens, J. H. M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.002 · Cited by 102
An overview of chemotoxicity and radiation toxicity in cancer therapy
Yazbeck, V. Y., Alesi, E. R., Myers, J., Hackney, M. H., Cuttino, L. W., & Gewirtz, D. A. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.03.007 · Cited by 102
Offer, S. M., Lee, A. M., Mattison, L. K., Fossum, C., Wegner, N. J., & Diasio, R. B. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.69 · Cited by 110
“These metabolites block cell cycle progression by inhibiting thymidylate synthase and incorporating into RNA and DNA.7 Some degree of tumor targeting occurs because the effects are most pronounced in rapidly dividing cancer cells; however, the effects are also felt system-wide, primarily in tissues with a high degree…”
BackgroundInfluentialHuynh, D. L., Sharma, N., Singh, A. K., Sodhi, S. S., Zhang, J., Mongre, R. K., Ghosh, M., Kim, N., Park, Y. H., & Jeong, D. K. (2017) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(17)30005-5 · Cited by 111
Tato-Costa, J., Casimiro, S., Pacheco, T. R., Pires, R., Fernandes, A., Alho, I., Pereira, P., Costa, P., Castelo, H. B., Ferreira, J. A., et al. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.09.003 · Cited by 126
“chemotherapy with the thymidylate synthase inhibitor 5fluorouracil (5-FU) and concomitant radiotherapy (chemoradiotherapy [CRT]), followed by surgery.(3,4)”
MethodMatošević, A., & Bosak, A. (2020) · Archives of Industrial Hygiene and Toxicology · doi:10.2478/aiht-2020-71-3466 · Cited by 101
“The first inhibits DNA synthesis and cell division by reducing normal thymidine production, and the second inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand (111, 112).”
BackgroundDrugs repurposed: An advanced step towards the treatment of breast cancer and associated challenges
Malik, J. A., Ahmed, S., Jan, B., Bender, O., Hagbani, T. A., Alqarni, A., & Anwar, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112375 · Cited by 113
DNA Repair in Mammalian Cells: Mismatched repair: variations on a theme
Kunz, C., Saito, Y., & Schär, P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-8739-9 · Cited by 143
MicroRNA-520g Confers Drug Resistance by Regulating p21 Expression in Colorectal Cancer
Zhang, Y., Geng, L., Talmon, G., & Wang, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.620252 · Cited by 100
“It acts principally as a thymidylate synthase inhibitor (1).”
BackgroundDrug Targets for Cancer Treatment: An Overview
Kumar, S. (2015) · Medicinal Chemistry · doi:10.4172/2161-0444.1000252 · Cited by 109
Human pyrimidine nucleotide biosynthesis as a target for antiviral chemotherapy
Ökesli, A., Khosla, C., & Bassik, M. C. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.03.010 · Cited by 110
Sekeres, M. J., Bradley-Garcia, M., Martínez-Canabal, A., & Winocur, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312697 · Cited by 110
“5-Fluorouracil’s (5-FU) primary mechanism of action is the inhibition of thymidine synthesis and blocking DNA replication [86]; 5-FU is capable of diffusing across the BBB [87,88] and directly impacting mitotic activity in the brain.”
BackgroundExcision of 5-Halogenated Uracils by Human Thymine DNA Glycosylase
Morgan, M. T., Bennett, M. T., & Drohat, A. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704253200 · Cited by 102
Metadata
- Authors
- Longley, D. B., Harkin, D. P., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Johnston, Patrick G.
- ORCID
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2003-05
- Volume
- 3
- Issue
- 5
- Pages
- 330-338
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1984328540
- Cited by
- 5,332
- References
- 111
- Citations by year
- 2026: 293 · 2025: 350 · 2024: 391 · 2023: 377 · 2022: 435 · 2021: 398 · 2020: 408 · 2019: 324 · 2018: 299 · 2017: 289 · 2016: 257 · 2015: 251 · 2014: 221 · 2013: 193 · 2012: 154
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- 5-fluorouracil, mechanism of action, drug resistance, predictive biomarkers, chemotherapeutic target, anticancer activity, cancer chemotherapy
- MeSH terms
- Animals, Antimetabolites, Antineoplastic, Fluorouracil, Humans, Interferons, Oxidoreductases, RNA, Thymidine Phosphorylase, Thymidylate Synthase, Biomarkers, Tumor Suppressor Protein p53, Microsatellite Repeats, Oligonucleotide Array Sequence Analysis, Dihydrouracil Dehydrogenase (NADP)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.